TIGIT inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “TIGIT inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 14+ companies and 18+ pipeline drugs in TIGIT inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
TIGIT inhibitors: Overview
T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is one of the most recent immune checkpoints to be investigated as an immunotherapeutic target. TIGIT is a transmembrane glycoprotein receptor with an Ig-like V-type domain and an ITIM in its cytoplasmic domain. It is expressed on activated and memory T cells, NK cells, and Tregs. Binding to either of its two ligands on APCs, CD155 (PVR: poliovirus receptor) and CD112 (PVRL2, nectin-2), prevents their maturation and confers a tolerogenic phenotype. Numerous clinical trials on TIGIT-blockade in cancer have recently been initiated, predominantly combination treatments. Mechanistally, research has shown that TIGIT-Fc fusion protein could interact with PVR on dendritic cells and increase its IL-10 secretion level/decrease its IL-12 secretion level under LPS stimulation, and also inhibit T cell activation in vivo. TIGIT's inhibition of NK cytotoxicity can be blocked by antibodies against its interaction with PVR and the activity is directed through its ITIM domain.
Report Highlights
This segment of the TIGIT inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TIGIT inhibitors Emerging Drugs
Further product details are provided in the report……..
TIGIT inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different TIGIT inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
TIGIT inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TIGIT inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIGIT inhibitors drugs.
TIGIT inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “TIGIT inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 14+ companies and 18+ pipeline drugs in TIGIT inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
TIGIT inhibitors: Overview
T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is one of the most recent immune checkpoints to be investigated as an immunotherapeutic target. TIGIT is a transmembrane glycoprotein receptor with an Ig-like V-type domain and an ITIM in its cytoplasmic domain. It is expressed on activated and memory T cells, NK cells, and Tregs. Binding to either of its two ligands on APCs, CD155 (PVR: poliovirus receptor) and CD112 (PVRL2, nectin-2), prevents their maturation and confers a tolerogenic phenotype. Numerous clinical trials on TIGIT-blockade in cancer have recently been initiated, predominantly combination treatments. Mechanistally, research has shown that TIGIT-Fc fusion protein could interact with PVR on dendritic cells and increase its IL-10 secretion level/decrease its IL-12 secretion level under LPS stimulation, and also inhibit T cell activation in vivo. TIGIT's inhibition of NK cytotoxicity can be blocked by antibodies against its interaction with PVR and the activity is directed through its ITIM domain.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence TIGIT inhibitors R&D. The therapies under development are focused on novel approaches for TIGIT inhibitors.
This segment of the TIGIT inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TIGIT inhibitors Emerging Drugs
- Tiragolumab: Genentech
- Ociperlimab: BeiGene
Further product details are provided in the report……..
TIGIT inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different TIGIT inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on TIGIT inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
TIGIT inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TIGIT inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIGIT inhibitors drugs.
TIGIT inhibitors Report Insights
- TIGIT inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing TIGIT inhibitors drugs?
- How many TIGIT inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TIGIT inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TIGIT inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for TIGIT inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Genentech
- BeiGene
- Arcus Biosciences
- iTeos Therapeutics
- Merck KGaA
- Curocell
- Agenus
- Compugen
- Tasrif Pharmaceutical
- Y-Biologics
- Aurigene
- Mereo BioPharma
- Phio pharmaceuticals
- Bio-Thera Solutions
- Tiragolumab
- Ociperlimab
- Domvanalimab
- EOS 448
- Etigilimab
- AGEN 1307
- PH 804-TME
- PH 804-ACT
- BAT6005
- Vibostolimab
- M-6223
- MK-7684A
- COM 902
- CRC 01
- YBL 027
- YBL 012
- AUNP-12
- TSRF 786C
- AB 308
- AGEN 1777
Introduction
Executive Summary
TIGIT inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
TIGIT inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Tiragolumab: Genentech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
MK-7684A: Merck
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
M 6223: Merck
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
TSRF 786C: Tasrif Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
TIGIT inhibitors Key Companies
TIGIT inhibitors Key Products
TIGIT inhibitors- Unmet Needs
TIGIT inhibitors- Market Drivers and Barriers
TIGIT inhibitors- Future Perspectives and Conclusion
TIGIT inhibitors Analyst Views
TIGIT inhibitors Key Companies
Appendix
Executive Summary
TIGIT inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
TIGIT inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Tiragolumab: Genentech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
MK-7684A: Merck
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
M 6223: Merck
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
TSRF 786C: Tasrif Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
TIGIT inhibitors Key Companies
TIGIT inhibitors Key Products
TIGIT inhibitors- Unmet Needs
TIGIT inhibitors- Market Drivers and Barriers
TIGIT inhibitors- Future Perspectives and Conclusion
TIGIT inhibitors Analyst Views
TIGIT inhibitors Key Companies
Appendix